The Business Unit is responsible for expanding Eurofarma's presence globally, acting in markets in which the Company does not yet have its own operations.
The Unit is one of the areas responsible for Eurofarma's international expansion, identifying the most attractive markets and establishing partnerships abroad, thereby increasing the presence of the Eurofarma brand and products outside Brazil in a profitable manner with a long-term vision.
Our products are exported to countries in Africa, Latin America, Asia, Europe, and the Middle East.
Our production facilities are certified by Anvisa (Brazil), Anmat and Cofepris (Argentina), Invima and Cofepris (Colombia), ISP - Public Health Institute (Chile), Department of Regulation and Control of Pharmaceutical Products and Similar (Guatemala), Digemid (Peru), and the Ministry of Public Health of Uruguay.
At the end of 2022, the Itapevi Unit was inspected by the FDA (U.S. Food and Drug Administration), the agency that regulates medications in the United States. The FDA granted Eurofarma a Voluntary Action Indicated (VAI) classification, indicating that the company meets the manufacturing standards required by the agency for good practices for future product approvals in the U.S. market.
We manufacture finished products with packaging in the desired language and with Eurofarma's layout, whether as branded or generic medications. Additionally, we provide all the necessary regulatory support for the registration of medications in your country.